Post by vissertrades on Jul 23, 2014 8:21:26 GMT -5
Advantages Of Administering Pain Drugs Via Inhalation Go Beyond Convenience
Friday 20 May 2011 - 5am PST
Pain / Anestheticsadd your opinionemailAdapted Media Release
Ratings for this article (click to rate)
Public / Patient:1 2 3 4 5
Health Professionals:1 2 3 4 5
The challenges of delivering drugs for treating pain - particularly in compromised patients - are well-documented. To address the risk and compliance factors associated with the administration of pain drugs, developers and researchers have been investigating inhalation - intranasal as well as oral inhalation - as a way to mitigate several of these issues. The market for inhaled pain drugs is currently dominated by products designed for intranasal delivery. But a number of drugs indicated for pain that are formulated for oral inhalation are winding their way through the development pipeline.
The potential advantages of pain drug inhalation have this group of therapeutics well-positioned to benefit from a number of market trends. As aging populations and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient-friendly and cost-effective.
Increased incidence in the general population and evolving pain management initiatives will drive growth in the pain product segment, as shifting patient demographics in developed societies increase demand for palliative treatments for conditions that include both nociceptive and neuropathic pain. And controlling pain associated with cancer is now considered an essential part of the practice of oncology.
A new research study from Greystone Associates, Inhaled Pain Management: Products, Therapeutics, Markets and Forecasts, examines the factors creating opportunities for inhalable pain management products. It identifies the key players in this segment, describes the regulatory and industry environment, and assesses the dynamics of patient care that will affect market development. The report also includes forecasts for the growth of inhaled pain management products.
Source:
Greystone Associates
www.greystoneassociates.org/Reports/Drug_Delivery/DPI/Dry_Powder_Inhalation.htm
Friday 20 May 2011 - 5am PST
Pain / Anestheticsadd your opinionemailAdapted Media Release
Ratings for this article (click to rate)
Public / Patient:1 2 3 4 5
Health Professionals:1 2 3 4 5
The challenges of delivering drugs for treating pain - particularly in compromised patients - are well-documented. To address the risk and compliance factors associated with the administration of pain drugs, developers and researchers have been investigating inhalation - intranasal as well as oral inhalation - as a way to mitigate several of these issues. The market for inhaled pain drugs is currently dominated by products designed for intranasal delivery. But a number of drugs indicated for pain that are formulated for oral inhalation are winding their way through the development pipeline.
The potential advantages of pain drug inhalation have this group of therapeutics well-positioned to benefit from a number of market trends. As aging populations and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient-friendly and cost-effective.
Increased incidence in the general population and evolving pain management initiatives will drive growth in the pain product segment, as shifting patient demographics in developed societies increase demand for palliative treatments for conditions that include both nociceptive and neuropathic pain. And controlling pain associated with cancer is now considered an essential part of the practice of oncology.
A new research study from Greystone Associates, Inhaled Pain Management: Products, Therapeutics, Markets and Forecasts, examines the factors creating opportunities for inhalable pain management products. It identifies the key players in this segment, describes the regulatory and industry environment, and assesses the dynamics of patient care that will affect market development. The report also includes forecasts for the growth of inhaled pain management products.
Source:
Greystone Associates
www.greystoneassociates.org/Reports/Drug_Delivery/DPI/Dry_Powder_Inhalation.htm